Prostate cancer is often asymptomatic in most men, underscoring the importance of regular screening for early detection.
Individuals are advised to consult their healthcare provider to assess their risk factors and explore screening options. The American Cancer Society advocates for informed decision-making by weighing the potential benefits, risks, and uncertainties associated with prostate cancer screening.
For men at average risk aged 55-69 with a life expectancy of at least 10 years, screening discussions should commence. Screening should occur biennially unless abnormal results prompt further evaluation.
Individuals at high risk for prostate cancer may undergo screening as early as 40 years old.
Given the slow-growing nature of prostate cancer, individuals without symptoms and a life expectancy of less than 10 years may not benefit from screening.
Early detection through screening often leads to the diagnosis of prostate cancer at a more treatable stage.
However, there are considerations to bear in mind:
- False positive PSA test results may necessitate prostate biopsies, carrying a slight risk of pain, infection, and bleeding.
- Prostate cancers vary in aggressiveness, with some posing minimal threat to health over a lifetime.
- Early detection may result in overtreatment and potential side effects from interventions like surgery or radiation.
Dr. Bharat K. Shah practices internal medicine at Advocate Health Care.
Looking for a healthcare provider? Explore options in Illinois or Wisconsin.